Company news

Marker Therapeutics, Inc. news in 2024

Marker Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

December 18, 2024

Marker Therapeutics Announces $16.1 Million Private Placement

December 18, 2024

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

December 16, 2024

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

December 9, 2024

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

November 25, 2024

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 13, 2024

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

August 13, 2024

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

August 11, 2024

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

April 7, 2024

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

March 24, 2024

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

March 21, 2024

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

January 21, 2024

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

January 7, 2024

Decks in 2024